You are here: Industry Insights > Top Story

News List

Novartis seeks to further tap into Chinese healthcare market firstwordpharma
April 03, 2019
Novartis CEO Vas Narasimhan indicated that the drugmaker aims to boost its presence in China by launching new products in the country and enhancing collaborations with local biotechnology and technology firms to...
NHS England set to save 300 million pounds per year after reaching deals on Humira biosimilars firstwordpharma
November 27, 2018
NHS England said Monday that it negotiated deals with drugmakers on biosimilar versions of AbbVie's Humira (adalimumab), potentially leading to annual savings of 300 million pounds
FDA grants expanded approval for Novartis' Promacta in first-line severe aplastic anaemia firstwordpharma
November 19, 2018
Novartis announced that the FDA has expanded the label for Promacta (eltrombopag) to include first-line treatment for adults and paediatric patients
FDA grants priority review to Roche's filing for Tecentriq in triple-negative breast cancer firstwordpharma
November 14, 2018
Roche said Tuesday that the FDA granted priority review to a filing seeking approval of Tecentriq (atezolizumab) plus chemotherapy for the first-line treatment of unresectable
Mylan, Theravance's Yupelri approved by FDA for COPD pharmafile
November 12, 2018
Mylan and Theravance Biopharma on Friday announced that the FDA approved Yupelri (revefenacin) as a maintenance treatment for patients with chronic obstructive
Amarin says detailed REDUCE-IT results bolster CV risk reduction claims for Vascepa, but some question whether placebo used may have exaggerated benefit pharmafile
November 12, 2018
Detailed data from the REDUCE-IT cardiovascular (CV) outcomes study of Amarin's Vascepa (icosapent ethyl) presented at the American Heart Association (AHA) meeting
UK parliamentary enquiry threatens to disclose details of Vertex, NHS negotiations over Orkambi pharmafile
November 12, 2018
The UK House of Commons' Health and Social Care Committee on Friday said that it requested documents from Vertex Pharmaceuticals, NHS England and the
NICE provisionally knocks back AstraZeneca's PARP inhibitor Lynparza in ovarian cancer maintenance setting pharmafile
November 12, 2018
The National Institute for Health and Care Excellence (NICE) issued draft guidance Friday recommending against routine NHS funding of AstraZeneca's Lynparza (olaparib) for
Merck & Co.'s Keytruda cleared by FDA for certain treatment-experienced patients with HCC pharmafile
November 12, 2018
Merck & Co. on Friday said Keytruda (pembrolizumab) has received accelerated approval from the FDA for the treatment of hepatocellular carcinoma (HCC) in patients
Merrimack to reduce workforce by 60 percent as ends development of cancer drug MM-121 firstwordpharma
November 09, 2018
Merrimack Pharmaceuticals announced plans to initiate a corporate restructuring that will see the drugmaker reduce expenses and slash its workforce by approximately...

Previous page 1 2 Next page